These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 22235855)
1. Expression of PDGFR-β and Kit in canine anal sac apocrine gland adenocarcinoma using tissue immunohistochemistry. Brown RJ; Newman SJ; Durtschi DC; Leblanc AK Vet Comp Oncol; 2012 Mar; 10(1):74-9. PubMed ID: 22235855 [TBL] [Abstract][Full Text] [Related]
2. Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers. Wilczynski SP; Chen YY; Chen W; Howell SB; Shively JE; Alberts DS Hum Pathol; 2005 Mar; 36(3):242-9. PubMed ID: 15791568 [TBL] [Abstract][Full Text] [Related]
3. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium. Schmandt RE; Broaddus R; Lu KH; Shvartsman H; Thornton A; Malpica A; Sun C; Bodurka DC; Gershenson DM Cancer; 2003 Aug; 98(4):758-64. PubMed ID: 12910520 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of expression and function of vascular endothelial growth factor receptor 2, platelet derived growth factor receptors-alpha and -beta, KIT, and RET in canine apocrine gland anal sac adenocarcinoma and thyroid carcinoma. Urie BK; Russell DS; Kisseberth WC; London CA BMC Vet Res; 2012 May; 8():67. PubMed ID: 22630170 [TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical analysis of expression of VEGFR2, KIT, PDGFR-β, and CDK4 in canine urothelial carcinoma. Setyo LC; Donahoe SL; Shearer PL; Wang P; Krockenberger MB J Vet Diagn Invest; 2023 Mar; 35(2):109-115. PubMed ID: 36648148 [TBL] [Abstract][Full Text] [Related]
6. PDGFR expression in differential diagnosis between KIT-negative gastrointestinal stromal tumours and other primary soft-tissue tumours of the gastrointestinal tract. Rossi G; Valli R; Bertolini F; Marchioni A; Cavazza A; Mucciarini C; Migaldi M; Federico M; Trentini GP; Sgambato A Histopathology; 2005 May; 46(5):522-31. PubMed ID: 15842634 [TBL] [Abstract][Full Text] [Related]
7. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Wyman K; Atkins MB; Prieto V; Eton O; McDermott DF; Hubbard F; Byrnes C; Sanders K; Sosman JA Cancer; 2006 May; 106(9):2005-11. PubMed ID: 16565971 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of the therapeutic potential of masitinib and expression of its specific targets c-Kit, PDGFR-α, PDGFR-β, and Lyn in canine prostate cancer cell lines. Klose K; Packeiser EM; Granados-Soler JL; Hewicker-Trautwein M; Murua Escobar H; Nolte I Vet Comp Oncol; 2022 Sep; 20(3):641-652. PubMed ID: 35384248 [TBL] [Abstract][Full Text] [Related]
9. Tyrosine kinase receptor status in endometrial stromal sarcoma: an immunohistochemical and genetic-molecular analysis. Cossu-Rocca P; Contini M; Uras MG; Muroni MR; Pili F; Carru C; Bosincu L; Massarelli G; Nogales FF; De Miglio MR Int J Gynecol Pathol; 2012 Nov; 31(6):570-9. PubMed ID: 23018215 [TBL] [Abstract][Full Text] [Related]
11. Receptor tyrosine kinase expression and phosphorylation in canine nasal carcinoma. Hocker SE; Higginbotham ML; Schermerhorn T; Henningson J Res Vet Sci; 2017 Dec; 115():484-489. PubMed ID: 28783596 [TBL] [Abstract][Full Text] [Related]
12. Protein expression of KIT and gene mutation of c-kit and PDGFRs in Ewing sarcomas. Do I; Araujo ES; Kalil RK; Bacchini P; Bertoni F; Unni KK; Park YK Pathol Res Pract; 2007; 203(3):127-34. PubMed ID: 17298867 [TBL] [Abstract][Full Text] [Related]